illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Catalent
Company logo

Catalent | Sustainability Performance

https://www.catalent.com

Provides advanced delivery technologies and development solutions for pharmaceuticals and biologics.

2007

United States

10,001+ employees

Biotechnology

$25M - 100M in revenue

Not profitable

Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.

Sustainability Ranking & Industry Benchmark

#12634
Overallⓘ
#2900
in United Statesⓘ
#244
in Biotechnologyⓘ

Sustainability Maturity

ⓘ
​​0123456789​​%

Sustainability Intent

ⓘ

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

13 out of 244

Overview
Environmental
Carbon emissionsDigital emissionsEnergy consumptionWater ManagementNature and biodiversity
Social
Diversity and InclusionPay GapsHealth and SafetyExternalities
Governance
SDG Impact
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies

Company logo
Arcturus Therapeutics

United States, Health Care, Biotechnology

Company logo
Biomarin Pharmaceutical

United States, Health Care, Biotechnology

Company logo
Insmed

United States, Health Care, Biotechnology

CO2 scope 1 + 2 ⓘDirect emissions from owned or controlled sources, combined with indirect emissions from purchased electricity calculated using grid-average emission factors based on where the energy is consumed.
257.0KCO2e tonnes, 2023
Critical
Renewable energy ⓘProportion of the company's total electricity consumption sourced from renewable sources, expressed as a percentage.
80%2024
Aligned
Female employees ⓘProportion of women in the company's total workforce, expressed as a percentage.
48%2024
Laggard
Externalities ⓘThe monetized estimate of environmental and social impacts caused by an organization that are not reflected in its financial accounts.
37.3M$, 2024
Leading
Market cap ⓘTotal market value of the company's outstanding shares, calculated by multiplying the share price by the number of shares outstanding.
11.5B$, 2024▼34% YoY
Revenue ⓘTotal revenue reported in the company's financial statements for the specified reporting year, reflecting income generated from primary business activities. Expressed in millions of USD.
4.4B$, 2024▼2.7% YoY

Controversy level

Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
  • Catalent faced multiple FDA Form 483 observations and warning letters at its Bloomington Indiana, Brussels and other gene therapy and biologics manufacturing facilities, affecting client production schedules including Novo Nordisk's GLP1 supply.
Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

 Available
image report
Available

Sustainability employees

ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.

Total sustainability employees

11+

ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.

    Available in
    Scale package

    Access
  • Email
  • Email